WO2023040103A1 - 立他司特的制备方法及其中间体化合物 - Google Patents

立他司特的制备方法及其中间体化合物 Download PDF

Info

Publication number
WO2023040103A1
WO2023040103A1 PCT/CN2021/139695 CN2021139695W WO2023040103A1 WO 2023040103 A1 WO2023040103 A1 WO 2023040103A1 CN 2021139695 W CN2021139695 W CN 2021139695W WO 2023040103 A1 WO2023040103 A1 WO 2023040103A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
reaction
organic
isopropyl
Prior art date
Application number
PCT/CN2021/139695
Other languages
English (en)
French (fr)
Inventor
王夏蔚
郑志国
Original Assignee
浙江大学医学院附属第一医院
浙江奥翔药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江大学医学院附属第一医院, 浙江奥翔药业股份有限公司 filed Critical 浙江大学医学院附属第一医院
Publication of WO2023040103A1 publication Critical patent/WO2023040103A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to the field of organic compound synthesis. Specifically, the present invention relates to a synthesis method of ritahast, a key intermediate for synthesizing ritahast and a preparation method thereof.
  • Litamistat (Lifitegrast), developed by Shire Pharmaceuticals, is a new type of small-molecule integrin inhibitor that can antagonize lymphocyte-associated antigens, block their interaction with their cognate ligands, intercellular adhesion molecules, and interfere with stem cells.
  • the overexpression of corneal and conjunctival tissues of eye diseases was approved by the US Food and Drug Administration (FDA) for marketing in the United States on July 11, 2016.
  • ritazast includes ester group hydrolysis or hydrogenation reaction of its precursor.
  • Scheme 1 WO2009139817A2, WO2011050175A1 and WO2019096996A1 disclose that the compound of formula II is hydrogenated under the catalysis of noble metal palladium carbon to obtain litamilast, but this route has noble metal residues and high production costs.
  • WO2019097547A1 can obtain Litamilast by alkali hydrolysis of the compound of formula III. Although the process seems simple, in actual production, the chiral amino acid derivatives are prone to racemization of the chiral configuration under strong alkaline conditions to produce impurity A, which is very unfavorable for the purification of ritazast.
  • the inventors unexpectedly discovered a method suitable for industrial production of ritahast during the research, which not only can effectively suppress the formation of impurity A, but also is simple to operate and can significantly reduce production costs. Moreover, the inventor has also obtained a new solvate crystal form of the compound of formula III.
  • the product purity can be greater than 99.9%, and the single impurity is less than 0.1%, or even equal to zero, and the crystal The preparation method of the form is simple, so the cost can be reduced, thereby solving the defects in the existing methods.
  • DMF N,N-dimethylformamide
  • DMA N,N-dimethylformamide
  • NMP N-methylpyrrolidone
  • DMSO dimethylsulfoxide
  • DIPEA N,N-diisopropylethylamine
  • THF tetrahydrofuran
  • alkyl refers to a straight or branched chain saturated hydrocarbon group composed of carbon atoms and hydrogen atoms. Preferably, the alkyl group has 1-10, eg 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 1 to 2 carbon atoms.
  • C 1-10 alkyl and “C 1-6 alkyl” refer to linear or branched saturated hydrocarbon groups having 1 to 10 and 1 to 6 carbon atoms, respectively.
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 2,2-di Methylbutyl, 2-methylpentyl, 2,3-dimethylbutyl, 3-methylpentane, cyclohexyl, n-heptyl or n-octyl.
  • alkoxy refers to the group R'-O-, wherein R' is an alkyl group as described above.
  • C 1-6 alkoxy refers to the group R'-O-, wherein R' is C 1-6 alkyl as described above.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • haloalkyl refers to an alkyl group as described above wherein one or more (eg 1, 2, 3, 4 or 5) hydrogen atoms are replaced by a halogen selected from the group consisting of fluorine, chlorine, bromine and iodine .
  • the haloalkyl is "C 1-10 haloalkyl” or "C 1-6 haloalkyl”. Examples thereof include, for example, -CH 2 F, -CHF 2 , -CF 3 , -CCl 3 , -C 2 F 5 , -C 2 Cl 5 , -CH 2 CF 3 , -CH 2 Cl, -CH 2 CH 2 CF 3 or -CF(CF 3 ) 2 .
  • haloalkoxy refers to an alkoxy group as described above, wherein one or more (eg 1, 2, 3, 4 or 5) hydrogen atoms are replaced by a halogen, wherein the halogen is selected from the group consisting of fluorine, chlorine, bromine and iodine.
  • the haloalkyl group is "C 1-10 haloalkoxy” or "C 1-6 haloalkoxy”. Examples thereof include, for example, -O-CH 2 F, -O-CHF 2 , -O-CF 3 , -O-CH 2 CF 3 , -O-CH 2 Cl, or -O-CH 2 CH 2 CF 3 .
  • cycloalkyl refers to a monocyclic, fused polycyclic, bridged polycyclic, or spiro non-aromatic saturated monovalent hydrocarbon ring structure having the indicated number of ring atoms.
  • Cycloalkyl groups can have from 3 to 12 carbon atoms (i.e., C3 - C12 cycloalkyl groups), such as 3 to 10, 3 to 8, 3 to 7, 3 to 6, or 5 to 6 carbons atom.
  • Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.
  • aryl refers to a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom in an aromatic ring system. Specifically, aryl refers to a monocyclic or fused polycyclic aromatic ring structure having the indicated number of ring atoms. For example, aryl includes groups containing 6 to 14, such as 6 to 10, preferably 6 ring atoms. Examples of aryl include C 6-14 aryl or C 6-10 aryl, such as phenyl or naphthyl, preferably phenyl.
  • aralkyl refers to an alkyl group as described above substituted by an aryl group as described above, eg C 6 -C 10 aryl-C 1-6 alkyl, eg benzyl.
  • Optionally substituted cycloalkyl means optionally replaced by one, two or three identical or different selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, C 1-6 Haloalkyl and C 1-6 haloalkoxy substituent substituted cycloalkyl such as C 3-8 cycloalkyl, for example by one, two or three selected from halogen, methyl, ethyl, n-propyl , isopropyl, n-butyl, isobutyl, tert-butyl, methoxy and ethoxy substituents substituted C 3-8 cycloalkyl.
  • Optionally substituted aryl means optionally replaced by one, two or three identical or different selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, C 1-6 haloalkane
  • Aryl group substituted with C 1-6 haloalkoxy substituent such as C 6 -C 10 aryl, such as phenyl, for example by one, two or three selected from halogen, methyl, ethyl, Phenyl substituted with substituents of n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy and ethoxy.
  • Optionally substituted aralkyl means optionally replaced by one, two or three identical or different selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, C 1-6 Haloalkyl and C 1-6 haloalkoxy substituent substituted aralkyl, such as C 6 -C 10 aryl-C 1-6 alkyl, such as benzyl, such as one, two or three selected Benzyl substituted by substituents from halogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy and ethoxy.
  • the present invention provides a method for preparing Ritahast, the method comprising:
  • R is selected from alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted aralkyl, preferably C 1-10 alkyl, C 6-10 aryl, or C 6-10 aryl-C 1-10 alkyl, such as C 1-6 alkyl or C 6-10 aryl-C 1-6 alkyl, particularly preferably methyl, ethyl, n-propyl, isopropyl , n-butyl, isobutyl, tert-butyl or benzyl, and
  • the basic condition is to carry out hydrolysis under the co-existence of inorganic base and organic base.
  • the inorganic base is selected from alkali metal or alkaline earth metal hydroxide, carbonate, bicarbonate, hydride or any combination thereof, such as lithium hydroxide, sodium hydroxide, hydrogen Potassium oxide, calcium hydroxide, Ba(OH) 2 , sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium hydride, and calcium hydride, or any two or more combination of species.
  • the organic base is selected from alkoxides, organic amines or any combination thereof, such as sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium tert-butoxide, potassium tert-butoxide, ethylamine , n-propylamine, isopropylamine, n-butylamine, ethylenediamine, dimethylethylenediamine, trimethylethylenediamine, tetramethylethylenediamine, trimethylamine, triethylamine, triethanolamine, DIPEA, pyridine, 4-Dimethylaminopyridine, imidazole, methylimidazole, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, piperazine, N-methylpiperazine, tetrabutylammonium hydroxide, N, Any one of N-dimethylaniline, N,N-dimethylcyclohexylamine,
  • the salt of the compound of formula I is selected from salts formed with organic acids or inorganic acids, preferably pharmaceutically acceptable salts, such as hydrochloride, sulfate, phosphate, nitrate, acetate or benzoate .
  • the solvate of the compound of formula I is selected from the compound of formula I or its salt and organic solvents such as methanol, ethanol, isopropanol, diethyl ether, tetrahydrofuran, methyl tetrahydrofuran, isopropyl ether, methyl tert-butyl ether, toluene, acetonitrile, acetone or butanone, preferably the solvate described in the second aspect below.
  • organic solvents such as methanol, ethanol, isopropanol, diethyl ether, tetrahydrofuran, methyl tetrahydrofuran, isopropyl ether, methyl tert-butyl ether, toluene, acetonitrile, acetone or butanone, preferably the solvate described in the second aspect below.
  • the method comprises one or more of the following steps:
  • step (2) adding the inorganic base and the organic base into purified water, stirring to dissolve, controlling the reaction temperature from -10 to 60°C, adding the solution prepared in step (1) dropwise into the aqueous base solution, and stirring until the reaction is complete;
  • step (3) after the solid is precipitated in step (3), it is filtered, washed with water, and dried at 20-70° C. to obtain the product of litahastast.
  • the yield is ⁇ 94.5%
  • the purity is ⁇ 99.8%
  • the ee value is ⁇ 99.8%
  • the single impurity is ⁇ 0.1%.
  • the reaction solvent is selected from water, organic solvents or mixtures thereof, such as methanol, ethanol, n-propanol, isopropanol, THF, methyl tetrahydrofuran, ether, isopropyl ether, methyl tertiary Butyl ether, 1,4-dioxane, ethyl acetate, isopropyl acetate, isopropyl formate, toluene, xylene, acetonitrile, DMF, DMA, NMP, DMSO, acetone, butanone, n-hexyl Any one of alkanes, cyclohexane, n-heptane and purified water or any combination of two or more.
  • organic solvents or mixtures thereof such as methanol, ethanol, n-propanol, isopropanol, THF, methyl tetrahydrofuran, ether, isopropyl ether,
  • step (2) the inorganic base and organic base are as described above.
  • the organic solvent for extraction is selected from aprotic organic solvents, such as toluene, methyl formate, ethyl formate, isopropyl formate, methyl acetate, ethyl acetate, isopropyl acetate, Any one of n-hexane, cyclohexane, n-heptane, diethyl ether, isopropyl ether, methyl tert-butyl ether, dichloromethane and chloroform, or any combination of two or more.
  • aprotic organic solvents such as toluene, methyl formate, ethyl formate, isopropyl formate, methyl acetate, ethyl acetate, isopropyl acetate, Any one of n-hexane, cyclohexane, n-heptane, diethyl ether, isopropyl ether, methyl tert-butyl
  • the acid is selected from organic acids or inorganic acids, such as any one or any two or more of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, benzoic acid combination of species.
  • the salt of the compound of formula I is selected from salts formed with organic acids or inorganic acids, preferably pharmaceutically acceptable salts, such as hydrochloride, sulfate, phosphate, nitrate, ethyl salts or benzoates.
  • Described solvate is selected from formula I compound or its salt and organic solvent such as methanol, ethanol, isopropanol, ether, tetrahydrofuran, methyl tetrahydrofuran, isopropyl ether, methyl tert-butyl ether, toluene, acetonitrile, acetone, Solvates formed by butanone.
  • the solvate of the compound of formula I is the solvate described in the second aspect below.
  • the present invention provides a solvate of the compound represented by formula IV.
  • the compound of formula IV is in crystalline form, characterized in that its X-ray powder diffraction pattern has characteristic diffractions at 6.12 ⁇ 0.2°, 20.12 ⁇ 0.2° and 20.94 ⁇ 0.2 expressed in 2 ⁇ diffraction angles peak.
  • the compound of formula IV is in a crystalline form, characterized in that its X-ray powder diffraction pattern has a 2 ⁇ diffraction angle at 6.12 ⁇ 0.2°, 17.40 ⁇ 0.2°, 17.70 ⁇ 0.2°, 20.12 Characteristic diffraction peaks at ⁇ 0.2°, 20.94 ⁇ 0.2° and 22.5 ⁇ 0.2°.
  • the compound of formula IV is in a crystalline form, characterized in that its X-ray powder diffraction pattern has a 2 ⁇ diffraction angle at 6.12 ⁇ 0.2°, 17.40 ⁇ 0.2°, 17.70 ⁇ 0.2°, 20.12 Characteristic diffraction peaks at ⁇ 0.2°, 20.94 ⁇ 0.2°, 22.5 ⁇ 0.2°, 22.78 ⁇ 0.2°, 26.14 ⁇ 0.2°, 26.74 ⁇ 0.2° and 26.98 ⁇ 0.2°.
  • the compound of formula IV is in crystalline form, characterized by having an X-ray powder diffraction pattern as shown in FIG. 1 .
  • the single crystal structure data of the formula IV compound of the present invention is as shown in Table 2, the atomic coordinates and the isotropic temperature factor of the formula IV compound molecule are as shown in Table 3, and the three-dimensional structure diagram of the formula IV compound molecule (solvent molecules are ignored) ) as shown in Figure 2, and the layered stacking diagram (along the ac direction) of the compound molecule of formula IV is shown in Figure 3.
  • the molecules of the compound of formula IV connect two molecules of the compound of formula IV into a molecular dimer through intermolecular hydrogen bonding NH...O, and the weak interaction between the molecules connects the molecular dimer into a layered stacking structure, and the THF molecule is in the In the middle of the molecular layer of the compound of formula IV.
  • the DSC curve of the crystal of the compound of formula IV of the present invention is shown in Figure 4, showing that its melting point is 146.5°C.
  • the present invention provides a method for preparing a solvate of formula IV, the method comprising:
  • step (a) is to add the crude product of formula III into the crystallization solvent, heat to dissolve, then cool down to crystallize, filter and dry to obtain the compound of formula IV in crystalline form.
  • the crystallization solvent is selected from: tetrahydrofuran, or tetrahydrofuran and methanol, ethanol, propanol, isopropanol, toluene, xylene, chlorobenzene, acetonitrile, 2-methyltetrahydrofuran, 1,4-dioxane Any one or two or more of hexane, dichloromethane, chloroform, ethyl acetate, isopropyl ether, methyl tert-butyl ether, hexane, n-hexane, cyclohexane, n-heptane mixture of solvents.
  • the dissolution temperature is 20-100°C.
  • the cooling and crystallization process is programmed cooling and crystallization, for example, the temperature is lowered at a rate of 5-15° C. per hour.
  • the crystallization is carried out by heat preservation for 0.5-10 hours, and then filtered to obtain a white wet product.
  • the wet white product is dried at a drying temperature of 10-70° C. to obtain the compound of formula IV in crystalline form.
  • the present invention provides a method for preparing Ritahast, which comprises starting from the solvate of Formula IV and hydrolyzing it under alkaline conditions to obtain Ritahast,
  • said alkaline condition is to carry out hydrolysis under the co-existence of inorganic base and organic base.
  • the inorganic base is selected from alkali metal or alkaline earth metal hydroxide, carbonate, bicarbonate, hydride or any combination thereof, such as lithium hydroxide, sodium hydroxide, hydrogen Potassium oxide, calcium hydroxide, barium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium hydride and calcium hydride, or any two or more combination.
  • the organic base is selected from alkoxides, organic amines or any combination thereof, such as sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium tert-butoxide, potassium tert-butoxide, ethylamine , n-propylamine, isopropylamine, n-butylamine, ethylenediamine, dimethylethylenediamine, trimethylethylenediamine, tetramethylethylenediamine, trimethylamine, triethylamine, triethanolamine, DIPEA, pyridine, 4-Dimethylaminopyridine, imidazole, methylimidazole, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, piperazine, N-methylpiperazine, tetrabutylammonium hydroxide, N, Any one of N-dimethylaniline, N,N-dimethylcyclohexylamine,
  • the method comprises one or more of the following steps:
  • step (3') after the solid is precipitated in step (3'), it is filtered, washed with water, and dried at 20-70° C. to obtain Litahast.
  • the yield is ⁇ 97.2%, the purity is ⁇ 99.8%, the ee value is ⁇ 99.8%, and the single impurity is ⁇ 0.1%.
  • reaction solvent is as described above in the first aspect.
  • the inorganic base and organic base described in step (2') are as described in the first aspect above.
  • the extraction solvent is as described in the first aspect above.
  • the method further comprises step (a) of the third aspect above.
  • the method comprises:
  • said alkaline condition is to carry out hydrolysis under the co-existence of inorganic base and organic base.
  • step (a) is as described in the third aspect above.
  • the reaction solvent described in step (b) is selected from water, organic solvents or mixtures thereof, such as methanol, ethanol, n-propanol, isopropanol, THF, methyl tetrahydrofuran, ether, isopropyl ether, methyl tert-butyl ether, 1,4-dioxane, ethyl acetate, isopropyl acetate, isopropyl formate, toluene, xylene, acetonitrile, DMF, DMA, NMP, DMSO, acetone, butyl Any one of ketone, n-hexane, cyclohexane, n-heptane and purified water or any combination of two or more.
  • organic solvents or mixtures thereof such as methanol, ethanol, n-propanol, isopropanol, THF, methyl tetrahydrofuran, ether, isopropyl
  • said step (b) comprises the above-mentioned steps (1'), (2') and (3').
  • steps (1'), (2'), (3') are as described for steps (1), (2), (3) in the corresponding embodiments of the first to third aspects above.
  • the present invention unexpectedly finds a method for preparing ritamilast by hydrolyzing a compound of formula I or formula IV in the presence of an organic base and an inorganic base.
  • the method has the advantages of high product purity, good ee value of the obtained product and few impurities, which overcomes the problems of low purity and ee value in the prior art, especially the solvate preparation using formula IV
  • the purity of the product can be greater than 99.9%, and the single impurity is less than 0.1%, or even zero.
  • the process of the method is simple, very suitable for industrial production, and can significantly reduce the cost.
  • Fig. 1 is the XRPD pattern of the crystal of the compound of formula IV.
  • Fig. 2 is a three-dimensional structure diagram of the crystal of the compound of formula IV (solvent molecules are ignored).
  • Figure 3 is a layered stacking diagram (along the ac direction) of the crystal of the compound of formula IV.
  • Fig. 4 is the DSC curve of the crystal of the compound of formula IV.
  • Fig. 5 is the DSC-TGA curve of the crystal of the compound of formula IV.
  • Embodiment 1 the preparation method of formula III compound
  • Embodiment 2 the preparation of formula IV compound
  • Embodiment 5 Preparation of Ritahast from Compound of Formula IV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种立他司特的制备方法及其中间体化合物。具体而言，涉及立他司特的合成方法、用于合成立他司特的关键中间体、其溶剂化物以及其在碱性条件下水解制备立他司特的方法。

Description

立他司特的制备方法及其中间体化合物 技术领域
本发明涉及有机化合物合成领域。具体而言，本发明涉及立他司特的合成方法、用于合成立他司特的关键中间体以及其制备方法。
背景技术
立他司特(Lifitegrast)是由Shire制药研发，是新型的小分子整合素抑制药，能拮抗淋巴细胞相关抗原，阻断其与其同源配体细胞间粘附分子的相互作用，干扰引起干眼病的角膜与结膜组织的过度表达，2016年7月11日获美国食品药品管理局(FDA)批准在美国上市销售。
Figure PCTCN2021139695-appb-000001
立他司特常见的制备方法包括其前体的酯基水解或氢化反应。如Scheme 1所示，WO2009139817A2、WO2011050175A1和WO2019096996A1公开了式II化合物在贵金属钯碳的催化作用下，氢化得到立他司特，但该路线有贵金属残留且生产成本较高。
Figure PCTCN2021139695-appb-000002
如Scheme 2所示，WO2019097547A1利用式III化合物的碱水解即可得到立他司特。该工艺虽然貌似简单，但在实际生产中，手性氨基酸衍生物在强碱性条件下，手性构型易发生消旋化而产生杂质A，十分不利于立他司特的纯化。
Figure PCTCN2021139695-appb-000003
针对现有方法的缺点，发明人在研究中意外地发现了一种适合于工业化生产立他司特的方法，不仅可以有效的抑制杂质A的生成，而且操作简单，能够显著降低生产成本。而且，发明人还获得一种式III化合物的新的溶剂化物的结晶形式，使用该结晶形式制备立他司特时，产品纯度可大于99.9％,单一杂质小于0.1％、甚至等于零，而且该结晶形式的制备方法简单，因此能够降低成本，从而解决现有方法中的缺陷。
发明内容
在本申请中，下列术语具有以下所述的含义：
“DMF”表示N,N-二甲基甲酰胺。
“DMA”表示N,N-二甲基甲酰胺。
“NMP”表示N-甲基吡咯烷酮。
“DMSO”表示二甲基亚砜。
“DIPEA”表示N,N-二异丙基乙胺。
“THF”表示四氢呋喃。
术语“烷基”是指由碳原子和氢原子组成的直链或支链的饱和烃基团。优选地，烷基具有1-10个，例如1至6个、1至5个、1至4个、1至3个或1至2个碳原子。术语“C 1-10烷基”和“C 1-6烷基”分别指具有1至10个和1至6个碳原子的直链或支链的饱和烃基团。烷基实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基、异戊基、新戊基、正己基、2,2-二甲基丁基，2-甲基戊基，2,3-二甲基丁基，3-甲基戊烷、环己基、正庚基或正辛基。
术语“烷氧基”表示基团R’-O-，其中R’是如上所述的烷基。“C 1-6烷氧基” 表示基团R’-O-，其中R’是如上所述的C 1-6烷基。
术语“卤素”是指氟、氯、溴或碘。
术语“卤代烷基”指上文所述的烷基，其中一个或多个(例如1、2、3、4或5个)氢原子被卤素代替，其中的卤素选自氟、氯、溴和碘。优选地，卤代烷基为“C 1-10卤代烷基”或“C 1-6卤代烷基”。其实例包括例如-CH 2F、-CHF 2、-CF 3、-CCl 3、-C 2F 5、-C 2Cl 5、-CH 2CF 3、-CH 2Cl、-CH 2CH 2CF 3或-CF(CF 3) 2。
术语“卤代烷氧基”指上文所述的烷氧基，其中一个或多个(例如1、2、3、4或5个)氢原子被卤素代替，其中的卤素选自氟、氯、溴和碘。优选地，卤代烷基为“C 1-10卤代烷氧基”或“C 1-6卤代烷氧基”。其实例包括例如-O-CH 2F、-O-CHF 2、-O-CF 3、-O-CH 2CF 3、-O-CH 2Cl、或-O-CH 2CH 2CF 3。
术语“环烷基”指具有指定环原子数的单环、稠合多环、桥接多环或螺环非芳族饱和单价烃环结构。环烷基可具有3至12个碳原子(即C 3-C 12环烷基)，例如3至10个，3至8个，3至7个，3至6个，或5至6个碳原子。环烷基的实例包括但不限于环丙基、环丁基、环戊基、环己基、环庚基或环辛基。
术语“芳基”是指通过从芳族环系统中的单个碳原子上移除一个氢原子而衍生的单价芳族烃基。具体地，芳基是指具有指定环原子数的单环或稠合多环芳族环结构。例如，芳基包括含有6至14个、例如6至10个、优选6个环原子的基团。芳基实例包括C 6-14芳基或C 6-10芳基，例如苯基或萘基，优选苯基。
术语“芳烷基”是指被如上所述的芳基取代的如上所述的烷基，例如C 6-C 10芳基-C 1-6烷基，例如苄基。
术语“任选取代的”是指该基团可以是未取代的或被一个或多个(例如1、2、3、4或5或更多个)取代基所取代，其中所述的取代基可以相同或不同。
“任选取代的环烷基”是指任选地被一个、两个或三个相同的或不同的选自C 1-6烷基、C 1-6烷氧基、卤素、C 1-6卤代烷基和C 1-6卤代烷氧基的取代基所取代的环烷基例如C 3-8环烷基，例如被一个、两个或三个选自卤素、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、甲氧基和乙氧基的取代基取代的C 3-8环烷基。
“任选取代的芳基”是指任选地被一个、两个或三个相同的或不同的选自C 1-6 烷基、C 1-6烷氧基、卤素、C 1-6卤代烷基和C 1-6卤代烷氧基的取代基所取代的芳基、例如C 6-C 10芳基、例如苯基，例如被一个、两个或三个选自卤素、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、甲氧基和乙氧基的取代基取代的苯基。
“任选取代的芳烷基”是指任选地被一个、两个或三个相同的或不同的选自C 1-6烷基、C 1-6烷氧基、卤素、C 1-6卤代烷基和C 1-6卤代烷氧基的取代基所取代的芳烷基、例如C 6-C 10芳基-C 1-6烷基、例如苄基，例如被一个、两个或三个选自卤素、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、甲氧基和乙氧基的取代基取代的苄基。
第一方面，本发明提供了一种制备立他司特的方法，该方法包括：
将式I化合物或其盐或溶剂化物在碱性条件下水解以得到立他司特，
Figure PCTCN2021139695-appb-000004
其中R选自烷基、卤代烷基、任选取代的环烷基、任选取代的芳基或任选取代的芳烷基，优选C 1-10烷基、C 6-10芳基、或C 6-10芳基-C 1-10烷基，例如C 1-6烷基或C 6-10芳基-C 1-6烷基，特别优选甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基或苄基，且
所述的碱性条件为在无机碱和有机碱共同存在下进行水解。
在一个优选的实施方案中，所述的无机碱选自碱金属或碱土金属的氢氧化物、碳酸盐、碳酸氢盐、氢化物或其任意组合，例如氢氧化锂、氢氧化钠、氢氧化钾、氢氧化钙、Ba(OH) 2、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、氢化钠、氢化钾和氢化钙中的任何一种或者任何两种或更多种的组合。
在一个优选的实施方案中，所述的有机碱选自醇盐、有机胺或其任意组合，例如甲醇钠、甲醇钾、乙醇钠、乙醇钾、叔丁醇钠、叔丁醇钾、乙胺、正丙胺、异丙胺、正丁胺、乙二胺、二甲基乙二胺、三甲基乙二胺、四甲基乙二胺、三 甲胺、三乙胺、三乙醇胺、DIPEA、吡啶、4-二甲氨基吡啶、咪唑、甲基咪唑、吗啉、N-甲基吗啉、哌啶、N-甲基哌啶、哌嗪、N-甲基哌嗪、四丁基氢氧化铵、N,N-二甲基苯胺、N,N-二甲基环己胺、六甲基磷酰三胺中的任何一种或者任何两种或更多种的组合。
所述的式I化合物的盐选自与有机酸或无机酸形成的盐，优选药学上可接受的盐，例如盐酸盐、硫酸盐、磷酸盐、硝酸盐、乙酸盐或苯甲酸盐。
在一个优选的实施方案中，所述的式I化合物的溶剂化物选自式I化合物或其盐与有机溶剂例如甲醇、乙醇、异丙醇、乙醚、四氢呋喃、甲基四氢呋喃、异丙醚、甲基叔丁基醚、甲苯、乙腈、丙酮或丁酮形成的溶剂化物，优选下文第二方面所述的溶剂化物。
在一个更优选的实施方案中，所述方法包括下述一个或多个步骤：
(1)将式I化合物或其盐或溶剂化物加入反应溶剂中，搅拌溶清；
(2)将无机碱和有机碱加入纯化水中，搅拌溶清，控制反应温度-10至60℃，将步骤(1)制备的溶液滴加至碱的水溶液中，搅拌至反应完毕；
(3)将反应混合物减压浓缩除去反应溶剂，有机溶剂萃取，加酸调节pH至1-4，析出固体，得到立他司特。
在一个具体的实施方案中，步骤(3)中析出固体后，过滤，水洗，并在20-70℃干燥得到立他司特产品。其收率≥94.5％，纯度≥99.8％，ee值≥99.8％，单一杂质≤0.1％。
在步骤(1)中，所述的反应溶剂选自水、有机溶剂或其混合物，例如甲醇、乙醇、正丙醇、异丙醇、THF、甲基四氢呋喃、乙醚、异丙醚、甲基叔丁基醚、1,4-二氧杂环己烷、乙酸乙酯、乙酸异丙酯、甲酸异丙酯、甲苯、二甲苯、乙腈、DMF、DMA、NMP、DMSO、丙酮、丁酮、正己烷、环己烷、正庚烷和纯化水中的任何一种或者任何两种或更多种的组合。
在步骤(2)中，所述的无机碱和有机碱如上所述。
在步骤(3)中，所述的萃取用有机溶剂选自非质子有机溶剂，例如甲苯、甲酸甲酯、甲酸乙酯、甲酸异丙酯、乙酸甲酯、乙酸乙酯、乙酸异丙酯、正己烷、环己烷、正庚烷、乙醚、异丙醚、甲基叔丁基醚、二氯甲烷和三氯甲烷中的任 何一种或者任何两种或更多种的组合。
在步骤(3)中，所述的酸选自有机酸或无机酸，例如盐酸、氢溴酸、硫酸、硝酸、磷酸、甲酸、乙酸、苯甲酸中的任何一种或者任何两种或更多种的组合。
在步骤(1)中，所述的式I化合物的盐选自与有机酸或无机酸形成的盐，优选药学上可接受的盐，例如盐酸盐、硫酸盐、磷酸盐、硝酸盐、乙酸盐或苯甲酸盐。所述的溶剂化物选自式I化合物或其盐与有机溶剂例如甲醇、乙醇、异丙醇、乙醚、四氢呋喃、甲基四氢呋喃、异丙醚、甲基叔丁基醚、甲苯、乙腈、丙酮、丁酮形成的溶剂化物。在一个优选的实施方案中，所述的式I化合物的溶剂化物是下文第二方面所述的溶剂化物。
第二方面，本发明提供了式IV所示的化合物的溶剂化物。
Figure PCTCN2021139695-appb-000005
在一个优选的实施方案中，式IV化合物为结晶形式，其特征在于，其X射线粉末衍射图谱具有以2θ衍射角表示的在6.12±0.2°、20.12±0.2°和20.94±0.2处的特征衍射峰。
在一个更优选的实施方案中，式IV化合物为结晶形式，其特征在于，其X射线粉末衍射图谱具有以2θ衍射角表示的在6.12±0.2°、17.40±0.2°、17.70±0.2°、20.12±0.2°、20.94±0.2°和22.5±0.2°处的特征衍射峰。
在一个更优选的实施方案中，式IV化合物为结晶形式，其特征在于，其X射线粉末衍射图谱具有以2θ衍射角表示的在6.12±0.2°、17.40±0.2°、17.70±0.2°、20.12±0.2°、20.94±0.2°、22.5±0.2°、22.78±0.2°、26.14±0.2°、26.74±0.2°和26.98±0.2°处的特征衍射峰。
在一个更优选的实施方案中，式IV化合物为结晶形式，其特征在于具有如图1所示的X射线粉末衍射图谱。
所述式IV化合物的结晶形式，当采用Cu-Kα
Figure PCTCN2021139695-appb-000006
辐射，管电压 40KV，管电流250mA，扫描速度5°/min，步宽0.02°，扫描范围3-50°(2θ)的θ-2θ连续扫描时，具有如图1所示的X射线粉末衍射图谱。其中，以2θ衍射角表示的主要特征衍射谱线如表1所示。
表1：式IV化合物的主要特征衍射谱线表
Figure PCTCN2021139695-appb-000007
本发明所述的式IV化合物的单晶结构数据如表2所示，式IV化合物分子 的原子坐标及各向同性温度因子如表3所示，式IV化合物分子的立体结构图(溶剂分子忽略)如图2所示，式IV化合物分子的层状堆叠图(沿ac方向)如图3所示。
上述结果表明，式IV化合物晶体属单斜晶系，C2(5#)空间群，晶胞参数为：
Figure PCTCN2021139695-appb-000008
β＝97.039(2)°，
Figure PCTCN2021139695-appb-000009
Figure PCTCN2021139695-appb-000010
Z＝4，分子式：C 30H 26Cl 2N 2O 7S·0.5(C 4H 8O)，晶体密度d＝1.403g/cm 3。其最小不对称单元中含有一个式IV化合物分子(结构式如图3所示)和半个四氢呋喃分子，四氢呋喃分子与式IV化合物分子之间没有氢键作用。式IV化合物分子间通过分子间氢键作用N-H…O将二个式IV化合物分子连接成分子二聚体，分子间的弱相互作用将此分子二聚体连接成层状堆叠结构，THF分子处于式IV化合物分子层中间。
表2式IV化合物分子的单晶结构数据和结构修正数据
Figure PCTCN2021139695-appb-000011
Figure PCTCN2021139695-appb-000012
表3式IV化合物分子的原子坐标及各向同性温度因子
Figure PCTCN2021139695-appb-000013
Figure PCTCN2021139695-appb-000014
本发明的式IV化合物晶体的DSC曲线如图4所示，表明其熔点为146.5℃。
本发明的式IV化合物晶体的DSC-TGA曲线如图5所示，表明其结构中含有约5.3％的溶剂。这与单晶衍射分析结果一致。从单晶衍射结果可知，式IV化合物交键中间体为THF溶剂合物，即结构中含有半个四氢呋喃分子，分子式为：C 30H 26C l2N 2O 7S·0.5(C 4H 8O)，分子量为665.57。半个四氢呋喃所占的重量比为：36.06/665.57*100％＝5.4％(四氢呋喃的分子量为72.11，半个四氢呋南 即为36.06)。
第三方面，本发明提供了一种制备式IV的溶剂化物的方法，该方法包括：
(a)将式III化合物粗品加入结晶溶剂中，溶解后降温析晶，得到结晶形式的式IV化合物，
Figure PCTCN2021139695-appb-000015
在一个具体实施方案中，步骤(a)是将式III粗品加入结晶溶剂中，加热溶清，然后降温析晶，过滤并干燥，得到结晶形式的式IV化合物。
所述的结晶溶剂选自：四氢呋喃，或者四氢呋喃与选自甲醇、乙醇、丙醇、异丙醇、甲苯、二甲苯、氯苯、乙腈、2-甲基四氢呋喃、1,4-二氧杂环己烷、二氯甲烷、氯仿、乙酸乙酯、异丙醚、甲基叔丁基醚、己烷、正己烷、环己烷、正庚烷中的任何一种或两种或两种以上的溶剂的混合物。
在一个具体实施方案中，溶清温度为20-100℃。
在一个具体实施方案中，降温析晶过程为程序化降温析晶，例如以每小时5-15℃的速度降温。
在一个具体实施方案中，当温度降至-10至25℃，保温析晶0.5-10h，然后过滤得白色湿品。将该白色湿品干燥，干燥温度为10-70℃，得到结晶形式的式IV化合物。
第四方面，本发明提供了一种制备立他司特的方法，该方法包括从式IV的溶剂化物开始，在碱性条件下水解得到立他司特，
Figure PCTCN2021139695-appb-000016
其中所述的碱性条件为在无机碱和有机碱共同存在下进行水解。
在一个优选的实施方案中，所述的无机碱选自碱金属或碱土金属的氢氧化物、碳酸盐、碳酸氢盐、氢化物或其任意组合，例如氢氧化锂、氢氧化钠、氢氧化钾、氢氧化钙、氢氧化钡、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、氢化钠、氢化钾和氢化钙中的任何一种或者任何两种或更多种的组合。
在一个优选的实施方案中，所述的有机碱选自醇盐、有机胺或其任意组合，例如甲醇钠、甲醇钾、乙醇钠、乙醇钾、叔丁醇钠、叔丁醇钾、乙胺、正丙胺、异丙胺、正丁胺、乙二胺、二甲基乙二胺、三甲基乙二胺、四甲基乙二胺、三甲胺、三乙胺、三乙醇胺、DIPEA、吡啶、4-二甲氨基吡啶、咪唑、甲基咪唑、吗啉、N-甲基吗啉、哌啶、N-甲基哌啶、哌嗪、N-甲基哌嗪、四丁基氢氧化铵、N,N-二甲基苯胺、N,N-二甲基环己胺、六甲基磷酰三胺中的任何一种或者任何两种或更多种的组合。
在一个更优选的实施方案中，所述方法包括下述一个或多个步骤：
(1’)将式IV的溶剂化物晶体加入反应溶剂中，搅拌溶清；
(2’)将无机碱和有机碱加入纯化水中，搅拌溶清，控制反应温度-10至60℃，将步骤(1’)制备的溶液滴加至碱的水溶液中，搅拌至反应完毕；
(3’)将反应混合物减压浓缩除去反应溶剂，有机溶剂萃取，加酸调节pH至1-4，析出固体，得到立他司特。
在一个优选的实施方案中，步骤(3’)中析出固体后，过滤，水洗，并在20-70℃干燥得到立他司特。其收率≥97.2％，纯度≥99.8％，ee值≥99.8％，单一杂质≤0.1％。
在一个优选的实施方案中，所述反应溶剂如上文第一方面所述。
在一个优选的实施方案中，在步骤(2’)中所述的无机碱和有机碱如上文第一方面所述。
在一个优选的实施方案中，所述的萃取用溶剂如上文第一方面所述。
在另一个实施方案中，所述方法还包括上述第三方面的步骤(a)。
在一个优选的实施方案中，所述方法包括：
(a)将式III化合物粗品加入结晶溶剂中，溶解后降温析晶，得到结晶形式的式IV的溶剂化物；和
(b)将式IV的溶剂化物晶体溶于反应溶剂并在碱性条件下水解得到立他司特，
Figure PCTCN2021139695-appb-000017
其中所述的碱性条件为在无机碱和有机碱共同存在下进行水解。
在一个优选的实施方案中，步骤(a)如上文第三方面所述。
在一个优选的实施方案中，步骤(b)所述的反应溶剂选自水、有机溶剂或其混合物，例如甲醇、乙醇、正丙醇、异丙醇、THF、甲基四氢呋喃、乙醚、异丙醚、甲基叔丁基醚、1,4-二氧六烷、乙酸乙酯、乙酸异丙酯、甲酸异丙酯、甲苯、二甲苯、乙腈、DMF、DMA、NMP、DMSO、丙酮、丁酮、正己烷、环己烷、正庚烷和纯化水中的任何一种或者任何两种或更多种的组合。
在一个更优选的实施方案中，所述步骤(b)包括上述的步骤(1’)、(2’)和(3’)。
对于步骤(1’)、(2’)、(3’)的条件，分别如上文第一至三方面的相应实施方案中对步骤(1)、(2)、(3)所述。
本发明出人意料地发现了一种使用式I或式IV的化合物在有机碱和无机碱存在的条件下水解制备立他司特的方法。令人惊讶地，该方法具有产品纯度高，所得产品ee值很好且杂质极少的优点，克服了现有技术中的纯度和ee值不高的问题，尤其是使用式IV的溶剂化物制备立他司特时，产品纯度可大于99.9％,单一杂质小于0.1％、甚至为零。而且，该方法的工艺简单，非常适合工业化生产，能够显著地降低成本。
附图说明
图1为式IV化合物晶体的XRPD图。
图2为式IV化合物晶体的立体结构图(溶剂分子忽略)。
图3为式IV化合物晶体的层状堆叠图(沿ac方向)。
图4为式IV化合物晶体的DSC曲线。
图5为式IV化合物晶体的DSC-TGA曲线。
具体实施方式
通过以下实施例对本发明的方法进行进一步的说明。应当理解，提供以下实施例的目的仅仅是为了能够更好的理解本发明，而不是以任何方式限定本发明的范围。
实施例1：式III化合物的制备方法
Figure PCTCN2021139695-appb-000018
方法1：
将化合物VI 46g、化合物V 14.5g、HATU 34.2g溶于DMF 460g，降温至-5至5℃。滴加三乙胺9.6g，滴毕，保温4-6小时反应。反应完毕，将反应液滴加到500g冰水中淬灭，过滤。滤饼用300g二氯甲烷溶解，水洗。收集有机层，浓缩至干，得到式III化合物粗品55.5g，收率100％，纯度95.6％。
方法2：
将化合物V 14.2g和0.1g DMF溶于45g二氯甲烷，升温至回流，滴加10.8g氯化亚砜，反应完成后浓缩至干，加入30g二氯甲烷溶解，然后滴加至预先配好的含有45g化合物VI的400g二氯甲烷溶液中，反应完成后，100g水洗两次，分液，有机相浓缩至干，得到式III化合物粗品54.3g，收率100％，纯度95.5％。
实施例2：式IV化合物的制备
Figure PCTCN2021139695-appb-000019
方法1：
称取20g式III化合物粗品置于圆底烧瓶中，加入30g四氢呋喃，升温回流溶解，然后加入10g甲基叔丁基醚，保温20～30分钟，自然降温析晶，至5-10℃时继续搅拌1.0-1.5h后，过滤得到白色结晶性粉末固体。45-55℃烘干，得18.9g，收率94.5％，纯度99.7％，最大单一杂质小于0.1％。
方法2：
称取30g式III化合物粗品置于反应瓶中，加入30g四氢呋喃和30g异丙醚，加热搅拌溶清，继续搅拌10～20分钟，程序降温析晶，每小时降温5-10℃，30-40℃时保温析晶1小时。然后继续降温搅拌析晶，至0-5℃时继续搅拌析晶1.0-1.5h，过滤，45-50℃烘干，得到28.5g白色结晶性粉末固体，收率95.0％，纯度99.7％，最大单一杂质小于0.1％。
方法3：
称取30g式III化合物粗品置于反应瓶中，加入35g四氢呋喃和15g正庚烷，搅拌，加热回流至完全溶解，继续搅拌10～20分钟，程序降温析晶，每小时降温5-15℃。降温至0-10℃时继续搅拌析晶1.0～1.5小时后，过滤，正庚烷洗涤，45-55℃烘干，得到28.6g白色结晶性粉末固体，收率95.3％，纯度99.8％，最大单一杂质小于0.1％。
实施例3：从式II化合物(即，式I化合物中R＝Bn)制备立他司特
Figure PCTCN2021139695-appb-000020
方法1(无机碱)：
将式II化合物70.6g加入600g乙腈中，搅拌溶清，待用。将11.2g氢氧化钾加入1000g纯化水中，搅拌溶清。控制反应温度-10至30℃，滴加上述配制的反应溶液至氢氧化钠水溶液中，滴毕，搅拌至反应完毕。减压浓缩除去反应溶剂，2×200g乙酸异丙酯萃取浓缩液，加盐酸调节pH＝1-4，析出固体，过滤，1000g水洗涤，50-60℃干燥得到立他司特55.6g，收率90.4％，纯度95.8％，ee 值95.6％，impurity A 4.4％。
方法2(无机碱+有机碱)：
将式II化合物70.6g加入600g乙腈中，搅拌溶清，待用。将11.2g氢氧化钾和15.0g三乙胺加入1000g纯化水中，搅拌溶清。控制反应温度-10至30℃，滴加上述配制的反应溶液至氢氧化钠水溶液中，滴毕，搅拌至反应完毕。减压浓缩除去反应溶剂，2×200g乙酸异丙酯萃取浓缩液，加盐酸调节pH＝1-4，析出固体，过滤，1000g水洗涤，50-60℃干燥得到立他司特58.3g，收率94.8％，纯度99.8％，ee值99.8％，impurity A 0.02％。
实施例4：从式III化合物(即，式I化合物中R＝Me)制备立他司特
Figure PCTCN2021139695-appb-000021
方法1(无机碱)：
将式III化合物63.0g加入600g丙酮中，搅拌溶清，待用。将10.0g氢氧化钠加入1000g纯化水中，搅拌溶清。控制反应温度-5至25℃，滴加上述配制的反应溶液至氢氧化钠水溶液中，滴毕，搅拌至反应完毕。减压浓缩除去反应溶剂，2×150g乙酸乙酯萃取浓缩液，加盐酸调节pH＝1-4，析出固体，过滤，1000g水洗涤，55-65℃干燥得到立他司特56.4g，收率91.7％，纯度96.2％，ee值94.8％，impurity A 5.2％。
方法2(无机碱+有机碱)：
将式III化合物63.0g加入600g丙酮中，搅拌溶清，待用。将10.0g氢氧化钠和19.4g DIPEA加入1000g纯化水中，搅拌溶清。控制反应温度-5至25℃，滴加上述配制的反应溶液至氢氧化钠水溶液中，滴毕，搅拌至反应完毕。减压浓缩除去反应溶剂，2×150g乙酸乙酯萃取浓缩液，加盐酸调节pH＝1-4，析出固体，过滤，1000g水洗涤，55-65℃干燥得到立他司特58.6g，收率95.3％，纯度99.8％，ee值99.9％，impurity A 0.01％。
实施例5：从式IV化合物制备立他司特
Figure PCTCN2021139695-appb-000022
方法1(无机碱)：
将式IV化合物66.6g加入800g四氢呋喃中，搅拌溶清，待用。将10.0g氢氧化钠加入1000g纯化水中，搅拌溶清。控制反应温度-5至20℃，滴加上述配制的反应溶液至氢氧化钠水溶液中，滴毕，搅拌至反应完毕。减压浓缩除去反应溶剂，2×190g甲苯萃取浓缩液，加盐酸调节pH＝1-4，析出固体，过滤，1100g水洗涤，50-70℃干燥得到立他司特56.8g，收率92.4％，纯度96.5％，ee值96.7％，impurity A 3.3％。
方法2(无机碱+有机碱)：
将式IV化合物66.6g加入800g四氢呋喃中，搅拌溶清，待用。将10.0g氢氧化钠和15.5g N-甲基哌啶加入1000g纯化水中，搅拌溶清。控制反应温度-5至20℃，滴加上述配制的反应溶液至氢氧化钠水溶液中，滴毕，搅拌至反应完毕。减压浓缩除去反应溶剂，2×190g甲苯萃取浓缩液，加盐酸调节pH＝1-4，析出固体，过滤，1100g水洗涤，50-70℃干燥得到立他司特59.8g，收率97.2％，纯度99.9％，ee值100％，impurity A 0％。

Claims (20)

  1. 制备立他司特的方法，该方法包括：
    将式I化合物或其盐或溶剂化物在碱性条件下水解以得到立他司特，
    Figure PCTCN2021139695-appb-100001
    其中R选自烷基、卤代烷基、任选取代的环烷基、任选取代的芳基或任选取代的芳烷基，优选C 1-10烷基、C 6-10芳基、或C 6-10芳基-C 1-10烷基，例如C 1-6烷基或C 6-10芳基-C 1-6烷基，特别优选甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基或苄基，且
    所述的碱性条件为在无机碱和有机碱共同存在下进行水解。
  2. 根据权利要求1所述的方法，其中所述无机碱选自碱金属或碱土金属的氢氧化物、碳酸盐、碳酸氢盐、氢化物或其任意组合，例如氢氧化锂、氢氧化钠、氢氧化钾、氢氧化钙、氢氧化钡、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、氢化钠、氢化钾和氢化钙中的任何一种或者任何两种或更多种的组合。
  3. 根据权利要求1-2任一项所述的方法，其中所述有机碱选自醇盐、有机胺或其任意组合，例如甲醇钠、甲醇钾、乙醇钠、乙醇钾、叔丁醇钠、叔丁醇钾、乙胺、正丙胺、异丙胺、正丁胺、乙二胺、二甲基乙二胺、三甲基乙二胺、四甲基乙二胺、三甲胺、三乙胺、三乙醇胺、DIPEA、吡啶、4-二甲氨基吡啶、咪唑、甲基咪唑、吗啉、N-甲基吗啉、哌啶、N-甲基哌啶、哌嗪、N-甲基哌嗪、四丁基氢氧化铵、N,N-二甲基苯胺、N,N-二甲基环己胺、六甲基磷酰三胺中的任何一种或者任何两种或更多种的组合。
  4. 根据权利要求1-3任一项所述的方法，其中所述的盐选自与有机酸或无机酸形成的盐，优选药学上可接受的盐，例如盐酸盐、硫酸盐、磷酸盐、硝酸盐、乙酸盐、苯甲酸盐。
  5. 根据权利要求1-4任一项所述的方法，其中所述方法包括下述一个或多个步骤：
    (1)将式I化合物或其盐或溶剂化物加入反应溶剂中，搅拌溶清；
    (2)将无机碱和有机碱加入纯化水中，搅拌溶清，控制反应温度-10至60℃，将步骤(1)制备的溶液滴加至碱的水溶液中，搅拌至反应完毕；
    (3)将反应混合物减压浓缩除去反应溶剂，有机溶剂萃取，加酸调节pH至1-4，析出固体，得到立他司特。
  6. 式IV所示的化合物
    Figure PCTCN2021139695-appb-100002
  7. 根据权利要求6所述的化合物，其中式IV化合物为结晶形式，其特征在于，其X射线粉末衍射图谱具有以2θ衍射角表示的在6.12±0.2°、20.12±0.2°和20.94±0.2处的特征衍射峰。
  8. 根据权利要求6所述的化合物，其中式IV化合物为结晶形式，其特征在于，其X射线粉末衍射图谱具有以2θ衍射角表示的在6.12±0.2°、17.40±0.2°、17.70±0.2°、20.12±0.2°、20.94±0.2°和22.5±0.2°处的特征衍射峰。
  9. 制备根据权利要求6所述的式IV化合物的方法，该方法包括：
    (a)将式III化合物粗品加入结晶溶剂中，溶解后降温析晶，得到结晶形式的式IV化合物，
    Figure PCTCN2021139695-appb-100003
  10. 根据权利要求9所述的方法，其中所述的结晶溶剂选自：四氢呋喃，或者四氢呋喃与选自甲醇、乙醇、丙醇、异丙醇、甲苯、二甲苯、氯苯、乙腈、2-甲基四氢呋喃、1,4-二氧杂环己烷、二氯甲烷、氯仿、乙酸乙酯、异丙醚、甲基叔丁基醚、己烷、正己烷、环己烷、正庚烷中的任何一种或两种或两种以上 的溶剂的混合物。
  11. 制备立他司特的方法，该方法包括从如权利要求6所述的式IV的溶剂化物开始，在碱性条件下水解得到立他司特，
    Figure PCTCN2021139695-appb-100004
    其中所述的碱性条件为在无机碱和有机碱共同存在下进行水解。
  12. 根据权利要求11所述的方法，其中所述的无机碱如权利要求2所述。
  13. 根据权利要求11-12任一项所述的方法，其中所述的有机碱如权利要求3所述。
  14. 根据权利要求11-13任一项所述的方法，其中所述方法包括下述一个或多个步骤：
    (1’)将式IV的溶剂化物晶体加入反应溶剂中，搅拌溶清；
    (2’)将无机碱和有机碱加入纯化水中，搅拌溶清，控制反应温度-10至60℃，将步骤(1)制备的溶液滴加至碱的水溶液中，搅拌至反应完毕；
    (3’)将反应混合物减压浓缩除去反应溶剂，有机溶剂萃取，加酸调节pH至1-4，析出固体，得到立他司特。
  15. 根据权利要求11-14任一项所述的方法，其中所述方法包括：
    (a)将式III化合物粗品加入结晶溶剂中，溶解后降温析晶，得到结晶形式的式IV的溶剂化物；和
    (b)将式IV的溶剂化物晶体溶于反应溶剂并在碱性条件下水解得到立他司特，
    Figure PCTCN2021139695-appb-100005
    其中所述的碱性条件为在无机碱和有机碱共同存在下进行水解。
  16. 根据权利要求15所述的方法，其中步骤(a)所述的结晶溶剂选自：四氢 呋喃，或者四氢呋喃与选自甲醇、乙醇、丙醇、异丙醇、甲苯、二甲苯、氯苯、乙腈、2-甲基四氢呋喃、1,4-二氧杂环己烷、二氯甲烷、氯仿、乙酸乙酯、异丙醚、甲基叔丁基醚、己烷、正己烷、环己烷、正庚烷中的任何一种或两种或两种以上的溶剂的混合物。
  17. 根据权利要求15-16任一项所述的方法，其中步骤(b)所述的反应溶剂选自水、有机溶剂或其混合物，例如甲醇、乙醇、正丙醇、异丙醇、THF、甲基四氢呋喃、乙醚、异丙醚、甲基叔丁基醚、1,4-二氧杂环己烷、乙酸乙酯、乙酸异丙酯、甲酸异丙酯、甲苯、二甲苯、乙腈、DMF、DMA、NMP、DMSO、丙酮、丁酮、正己烷、环己烷、正庚烷和纯化水中的任何一种或者任何两种或更多种的组合。
  18. 根据权利要求15-17任一项所述的方法，其中步骤(b)包括如权利要求14所述的步骤(1’)、(2’)和(3’)。
  19. 根据权利要求5所述的方法，其中所述的反应溶剂选自水、有机溶剂或其混合物，例如甲醇、乙醇、正丙醇、异丙醇、THF、甲基四氢呋喃、乙醚、异丙醚、甲基叔丁基醚、1,4-二氧杂环己烷、乙酸乙酯、乙酸异丙酯、甲酸异丙酯、甲苯、二甲苯、乙腈、DMF、DMA、NMP、DMSO、丙酮、丁酮、正己烷、环己烷、正庚烷和纯化水中的任何一种或者任何两种或更多种的组合。
  20. 根据权利要求5和14-18任一项所述的方法，其中所述萃取用的有机溶剂选自非质子有机溶剂，例如甲苯、甲酸甲酯、甲酸乙酯、甲酸异丙酯、乙酸甲酯、乙酸乙酯、乙酸异丙酯、正己烷、环己烷、正庚烷、乙醚、异丙醚、甲基叔丁基醚、二氯甲烷和三氯甲烷中的任何一种或者任何两种或更多种的组合。
PCT/CN2021/139695 2021-09-18 2021-12-20 立他司特的制备方法及其中间体化合物 WO2023040103A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111110390.4A CN113880819A (zh) 2021-09-18 2021-09-18 立他司特的制备方法及其中间体化合物
CN202111110390.4 2021-09-18

Publications (1)

Publication Number Publication Date
WO2023040103A1 true WO2023040103A1 (zh) 2023-03-23

Family

ID=79009892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/139695 WO2023040103A1 (zh) 2021-09-18 2021-12-20 立他司特的制备方法及其中间体化合物

Country Status (2)

Country Link
CN (1) CN113880819A (zh)
WO (1) WO2023040103A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024001995A1 (zh) * 2022-06-27 2024-01-04 浙江海翔药业股份有限公司 一种立他司特吗啉盐及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN106995439A (zh) * 2016-01-26 2017-08-01 镇江圣安医药有限公司 氘取代3‑(甲磺酰基)‑l‑苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
WO2019097547A1 (en) 2017-11-15 2019-05-23 Cipla Limited An improved process for the preparation of lifitegrast or salts thereof
WO2019096996A1 (en) 2017-11-17 2019-05-23 Medichem, S.A. A process to obtain a tetrahydroisoquinoline derivative
WO2021107514A2 (ko) * 2019-11-27 2021-06-03 연성정밀화학(주) 리피테그라스트의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
CN104797574B (zh) * 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN106995439A (zh) * 2016-01-26 2017-08-01 镇江圣安医药有限公司 氘取代3‑(甲磺酰基)‑l‑苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
WO2019097547A1 (en) 2017-11-15 2019-05-23 Cipla Limited An improved process for the preparation of lifitegrast or salts thereof
WO2019096996A1 (en) 2017-11-17 2019-05-23 Medichem, S.A. A process to obtain a tetrahydroisoquinoline derivative
WO2021107514A2 (ko) * 2019-11-27 2021-06-03 연성정밀화학(주) 리피테그라스트의 제조방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024001995A1 (zh) * 2022-06-27 2024-01-04 浙江海翔药业股份有限公司 一种立他司特吗啉盐及其制备方法和应用

Also Published As

Publication number Publication date
CN113880819A (zh) 2022-01-04

Similar Documents

Publication Publication Date Title
TWI411602B (zh) 製造整合酶抑制劑的方法及彼所用的中間物
JP2018537436A (ja) ジヒドロピリド環化合物の結晶形、製造方法および中間体
KR102266680B1 (ko) 벨리노스테트의 다형태 및 이의 제조 방법
JP5531097B2 (ja) アンブリセンタンを調製するための改善された方法およびその新規な中間体
US9663550B2 (en) Method for preparing abiraterone acetate
WO2023040103A1 (zh) 立他司特的制备方法及其中间体化合物
WO2015165320A1 (zh) 瑞戈非尼盐及其晶型、制备方法
CN110606842B (zh) 吡啶胺基嘧啶衍生物的制备方法及其中间体
WO2017122139A1 (en) An improved process for the preparation of pirfenidone
WO2016169533A1 (en) A solid form of apremilast and a process for preparing the same
JP2019147763A (ja) プロリンアミド化合物の製造方法
TWI541235B (zh) 製備喹唑啉衍生物之方法
JP5302199B2 (ja) ３−（１ｈ−インドル−３−イル）−４−［２−（４−メチル−ピペラジン−１−イル）−キナゾリン−４−イル］−ピロール−２，５−ジオンの結晶形態
WO2018133533A1 (zh) 孟鲁司特钠中间体及其制备方法和应用
CN109988070B (zh) 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用
WO2008090565A1 (en) Novel thermodynamically stable polymorphic form-l of letrozole
WO2022152315A1 (zh) 一种合成氨基嘧啶类fak抑制剂化合物的方法
WO2020020190A1 (zh) 一种喹啉衍生物的合成方法
WO2017193913A1 (zh) 一种福沙匹坦磷酸酯中间体及其制备方法
TWI823341B (zh) 製備鞘胺醇－１－磷酸酯受體促效劑的新穎方法
WO2013067664A1 (zh) 制备齐多夫定及其中间体的方法
WO2020238753A1 (zh) 一种水杨胺醋酸盐的制备方法
JP2002521383A (ja) リンチトリプトのカリウム塩の製造法
CN117186150A (zh) 一种lfa-1抑制剂的制备方法
JPWO2021027813A5 (zh)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21957367

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021957367

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021957367

Country of ref document: EP

Effective date: 20240418